Dura Pharmaceuticals, Inc.

NEW YORK and SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the promotion of Cofounder Cam Gallagher, MBA, to President. Mr. Gallagher, who previously served as an Executive Director of Zentalis, will remain a member of the Board of Directors, which he has served on since the Company’s founding. He will report to Chief Executive Officer Dr. Kimberly Blackwell. “Cam is a seasoned life sciences veteran with thirty years of operational, transactional and leadership experience and has been an integral Zentalis team member since its conception,” commented Dr. Kimberly Blackwell, Chief Executive Officer of Zentalis Pharmaceuticals. “In his new role, Cam will lead the corporate and business development initiatives, implementing strategies that will be imperative to achieving our clinical and corporate goals. We are excited to have Cam on board as a full-time management team member.” “Over the last seven years, I have had the privilege of working closely with the Zentalis team and supporting the Company’s rapid growth and development,” said Cam Gallagher, Cofounder, President and Director of Zentalis Pharmaceuticals. “I am confident in the therapeutic potential of Zentalis’ lead assets ZN-c3 and ZN-d5 as the Company drives its exciting clinical strategy forward and I am pleased to join the management team under Kim’s leadership to provide our potentially life changing oncology treatments to patients in need.” Previously, Mr. Gallagher served as the Chief Business Officer at Immusoft Corporation, a preclinical gene therapy company. He currently serves on the Board of Directors for Ocuphire, Helios, SelectION and Ray Therapeutics. Mr. Gallagher has also previously served on the Board of Directors for numerous oncology and gene therapy biotech companies, including VelosBio until its acquisition by Merck, Oncternal Therapeutics, Inc., where he also served as the Head of Corporate Development, Retrosense Therapeutics, LLC, where he also served as Chief Business Officer until its acquisition by Allergan, and Sorrento Therapeutics, Inc. Prior to these roles, he held leadership positions at Oncternal, Zavante, Verus Pharma, CV Therapeutics and Dura Pharma. Mr. Gallagher received an MBA from the University of San Diego and a BS in Business Administration from Ohio University. About Zentalis PharmaceuticalsZentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders, ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-e4, an EGFR inhibitor for non-small cell lung carcinoma (NSCLC) and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. The Company has licensed ZN-c3, ZN-d5 and ZN-c5 to its joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China. Zentalis has operations in both New York and San Diego. For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the development, potential, safety, efficacy, and regulatory and clinical progress of our product candidates in the United States and globally; creating long-term value for shareholders; and the impact of management and personnel changes on our business, operations and financial results. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of our lead product candidates; the outcome of preclinical testing and early trials may not be predictive of the success of later clinical trials; failure to identify additional product candidates and develop or commercialize marketable products; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel, and risks relating to management transitions; significant costs as a result of operating as a public company; the COVID-19 pandemic has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials; and the other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 filed with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Investor Contact: Alexandra RoySolebury Troutaroy@soleburytrout.com Media Contact: Julia DeutschSolebury Troutjdeutsch@soleburytrout.com

Dura Composites (Essex, U.K.) a global supplier of composite grating, walkways, access structures, profiles and risers, has recently launched a new online tool, the Interactive Product Selector, which the company says will help unlock the world of composite products for a vast range of architects, engineers, project managers and designers. With additional access to its new range of d2 Dura Grating series, the Interactive Product Selector is now available on Dura Composites’ website to help those within the industrial, construction, civil and facilities management industries to make fast and accurate decisions about the right product specification for their projects. Further, the tool is said to provide invaluable assistance at all stages of a user’s project lifecycle. When considering walkway floor grating for example, users can choose their preferred product surface type (standard mesh, mini mesh or covered) and then input data relating to the project to narrow down product choice. The selections include the clear span dimension; the type of load (point load or uniformly distributed load); the maximum load requirement; the allowable deflection criteria (measured as a proportion of the span, i.e. L/200 or 0.5%); and the fire rating required. These filters are said to ensure that the resulting product selections meet the needs of the project specification. Once a range of suitable products have been identified, detailed product information can be accessed immediately such as drawings, dimensions, load tables and graphs unique to these products. The selected span and load criteria can be downloaded into a neat professional document for analysis and approval. Users can also compare products across the Dura Composites range with the click of a button the company says, with easy-to-interpret graphs collated into a single view. BIM data files which feature product information can also be downloaded from the tool, allowing architects and specifiers to streamline the design, build and maintenance process for time and cost savings. According to Dura Composites, the Interactive Product Selector also streamlines a user’s selection of its d2 GRP Dura profile beam section, which bases it on whatever traditional beam may already be featured on a drawing. The specific steel or timber beam type and size can be selected from a drop-down list, the load criteria chosen alongside the span and the Selector Tool will generate which GRP Dura profiles meet or exceed the performance of steel or timber, as well as safety factor data. Notable is the ability to compare GRP from other suppliers with Dura’s next-generation d2 materials, the company says. According to live test data, a d2 Dura profile has an average tensile modulus of more than 31GPa, which is said to far exceed the requirement of 23GP set out by the E23 European standard within BS EN 13706. This means that d2 Dura profiles are on average 88% stronger than other GRP profiles. The result, says Dura, is that a smaller, lighter and more cost-effective profile section can be used such as a 50 x 50 mm box section as opposed to a 64 x 64 mm size, saving 20% in weight. To further help those who are new to the composites industry, Dura says its tool also features a Materials Properties section which allows users to delve into detail regarding each product range and a Property Comparison tool which enables visitors to compare how Dura Composites materials compare against more traditional materials used in construction, as well as against typical composite materials from other suppliers. These include specific strength, tensile strength, expansion, electrical resistivity and thermal conductivity. The tool can be accessed at .